Literature DB >> 7685696

High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy.

A Gelet1, J Y Chapelon, J Margonari, Y Theillère, F Gorry, R Souchon, R Bouvier.   

Abstract

High intensity-focused ultrasound (HIFU) has been used transrectally to induce an intraprostatic coagulation necrosis lesion in human prostatic adenoma. The device to produce HIFU combines a firing system (power amplifier and therapy transducer) and an imaging system (ultrasound scanner). Nine patients have been treated on epidural anaesthesia with an ultrasound intensity similar to or higher than the acoustic intensity used in previous experiments on canine prostates. Intraprostatic lesions were obtained without any damage to the rectal wall. These lesions were also histologically determined to be coagulation necrosis with a complete destruction of the glandular tissue. These studies confirm the possibility of creating irreversible lesions in the prostatic tissue through the rectal wall. The destruction of localised prostatic cancer would seem to be possible in the near future by using HIFU delivered by the transrectal route.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685696     DOI: 10.1159/000474679

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

1.  Visualization of HIFU-induced lesion boundaries by axial-shear strain elastography: a feasibility study.

Authors:  Arun K Thittai; Belfor Galaz; Jonathan Ophir
Journal:  Ultrasound Med Biol       Date:  2011-01-26       Impact factor: 2.998

2.  MRI-compatible positioning device for guiding a focused ultrasound system for transrectal treatment of prostate cancer.

Authors:  Christos Yiallouras; Nicos Mylonas; Christakis Damianou
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-12-13       Impact factor: 2.924

3.  Transcostal high-intensity-focused ultrasound: ex vivo adaptive focusing feasibility study.

Authors:  J-F Aubry; M Pernot; F Marquet; M Tanter; M Fink
Journal:  Phys Med Biol       Date:  2008-05-12       Impact factor: 3.609

4.  Sequential changes in rat femoral artery blood flow and tissue degeneration after exposure to high-intensity focused ultrasound.

Authors:  Tetsuya Ishikawa; Takashi Okai; Kazuaki Sasaki; Shin-Ichiro Umemura; Nozomi Miyazaki; Miki Kushima; Hiroko Aoki; Mitsuyoshi Ichihara; Kiyotake Ichizuka
Journal:  J Med Ultrason (2001)       Date:  2008-12-16       Impact factor: 1.314

5.  Coagulation of human prostate volumes with MRI-controlled transurethral ultrasound therapy: results in gel phantoms.

Authors:  William Apoutou N'djin; Mathieu Burtnyk; Ilya Kobelevskiy; Stefan Hadjis; Michael Bronskill; Rajiv Chopra
Journal:  Med Phys       Date:  2012-07       Impact factor: 4.071

6.  High intensity focused ultrasound in clinical tumor ablation.

Authors:  Yu-Feng Zhou
Journal:  World J Clin Oncol       Date:  2011-01-10

Review 7.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

Review 8.  Focal therapy in prostate cancer: modalities, findings and future considerations.

Authors:  Uri Lindner; John Trachtenberg; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

9.  MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapy.

Authors:  Elizabeth Ramsay; Charles Mougenot; Max Köhler; Michael Bronskill; Laurence Klotz; Masoom A Haider; Rajiv Chopra
Journal:  J Magn Reson Imaging       Date:  2013-02-25       Impact factor: 4.813

10.  Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI.

Authors:  Olivier Rouvière; Nicolas Girouin; Ludivine Glas; Alexandre Ben Cheikh; Albert Gelet; Florence Mège-Lechevallier; Muriel Rabilloud; Jean-Yves Chapelon; Denis Lyonnet
Journal:  Eur Radiol       Date:  2009-08-19       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.